Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2026-07-06 @ 1:45 AM
Study NCT ID:
NCT03483103
Status:
COMPLETED
Last Update Posted:
2023-12-20
First Post:
2018-03-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Sponsor:
Juno Therapeutics, a Subsidiary of Celgene
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
017006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None